RAMM Pharma Corp.

Equities

RAMM

CA75150G1046

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 11:12:06 16/05/2024 pm IST 5-day change 1st Jan Change
0.04 CAD 0.00% Intraday chart for RAMM Pharma Corp. 0.00% -27.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
RAMM Pharma Corp. cancelled the transaction announced on September 5, 2023 CI
RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
RAMM Pharma Corp. Announced Corporate Update; Looking At Legal Options Around Private Placement; Rose 28% on Friday MT
RAMM Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
RAMM Pharma Drops 30% As Says Seeking Advice After CSE Required Shareholder Approval For Private Placement MT
RAMM Pharma Seeking Advice After CSE Required Shareholder Approval For Private Placement MT
RAMM Pharma Corp. announces an Equity Buyback for 5% of its issued share capital. CI
RAMM Pharma Corp. announced that it expects to receive CAD 1 million in funding CI
RAMM Pharma Corp. authorizes a Buyback Plan. CI
RAMM Pharma Corp.'s Equity Buyback announced on August 17, 2022, has expired. CI
RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2023 CI
RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2022 CI
RAMM Pharma Names Interim CFO MT
RAMM Pharma Corp. Announces Chief Financial Officer Changes CI
RAMM Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022 CI
The Green Organic Dutchman Closes Sale of HemPoland Subsidiary MT
RAMM Pharma Says to Start Normal Course Issuer Bid MT
RAMM Pharma Corp. announces an Equity Buyback for 5% of its issued share capital. CI
RAMM Pharma Corp. authorizes a Buyback Plan. CI
RAMM Pharma Corp.'s Equity Buyback announced on July 6, 2021 has expired. CI
RAMM Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022 CI
RAMM Pharma Corp. Reports Earnings Results for the First Quarter Ended January 31, 2022 CI
RAMM Pharma Corp. Reports Earnings Results for the Full Year Ended October 31, 2021 CI
Chart RAMM Pharma Corp.
More charts
RAMM Pharma Corp. is a Canada-based company that is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a diversified international production and sales platform. The Company operates a pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or use in several Latin American countries. The Company has a pipeline of products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at its formulation facility in Montevideo, Uruguay. The Company's brands include NettaPet and NettaVet. Its subsidiaries include Canapar Corp., HemPoland S.p. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
More about the company
  1. Stock Market
  2. Equities
  3. RAMM Stock
  4. News RAMM Pharma Corp.
  5. RAMM Pharma Corp. Announced Corporate Update; Looking At Legal Options Around Private Placement; Rose 28% on Friday
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW